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Abstract
Maintenance of telomere length during cell division is dependent on the catalytic subunit
telomerase reverse transcriptase (TERT), which adds TTAGGG repeats to the ends of
chromosomes to prevent telomere shortening during DNA replication. However, nontelomeric roles of TERT have emerged under oxidative stress whereby TERT translocates
from the nucleus to the mitochondria and protects against mitochondrial dysfunction through
a poorly defined mechanism. A major pathological feature of Alzheimer’s Disease (AD) is
the progressive accumulation of amyloid-beta (Aβ) peptide within the cortex and
hippocampus. Aβ can directly interfere with mitochondrial respiration and promote
mitochondrial dysfunction, ROS production, and neuronal cell death. A shift in metabolism
away from oxidative phosphorylation towards aerobic glycolysis has been shown to confer
neuroprotection against A toxicity. Hence, it was hypothesized that elevated TERT
expression can protect neurons from mitochondrial dysfunction and Aβ toxicity via
metabolic reprogramming. TERT overexpression in the neuronal cell line HT22 promoted a
shift towards aerobic glycolysis by altering levels of glycolytic enzymes following exposure
to H2O2 and Aβ. Furthermore, TERT overexpression decreased mitochondrial ROS levels
and improved cell viability during oxidative stress. Following exposure to H2O2 and Aβ,
TERT translocation to the cytoplasm and mitochondria was observed. The results from this
study suggest that TERT may be a therapeutic target for potential treatment of AD.
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mitochondria, reactive oxygen species, oxidative stress, amyloid-beta, Alzheimer’s Disease
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Chapter 1: Introduction and Literature Review
1.1

Telomerase and TERT

1.1.1

Telomerase and associated proteins

Telomeres are specialized structures located on the ends of chromosomes that are
comprised of double stranded guanine (G)-rich hexanucleotide tandem repeats
(TTAGGG) followed by a single stranded TTAGGG overhang. The primary function of
telomeres is to prevent linear DNA from being recognized as a broken end, thereby
preventing DNA end-to-end joining and DNA degradation1. However, DNA polymerases
are unable to replicate the extreme ends of the 5’ strand during DNA replication resulting
in a progressive loss of telomeres from chromosomes after each cell division. This
phenomenon is known as the end-replication problem2. Consequently, the shortening of
telomeres to a critical length, termed the Hayflick limit, leads to a loss of proliferation
and initiation of cellular senescence3,4. Telomere attrition has been used as a biomarker
for aging and is associated with many age-related diseases such as compromised immune
function, various cancers, cardiovascular diseases and cognitive disorders4–6.
Fortunately, telomere length can be preserved by the eukaryotic protein telomerase.
Telomerase is a dimeric protein comprised of two main subunits; telomerase RNA
component (TERC) and telomerase reverse transcriptase (TERT)7. Telomerase
recognizes the hydroxyl group at the telomeric 3’ overhang and uses the TERC RNA
template to catalytically add TTAGGG nucleotide repeats to telomeres7. In addition, the
maintenance of telomeres relies on the shelterin complex which is required for the
protection and stability of telomeres in a conserved T-loop configuration8. The shelterin
complex is composed of six major subunits: telomeric repeat binding factor 1 and 2
(TRF1, TRF2), TRF1-interacting nuclear factor 2 (TIN2), protection of telomeres protein
1 (POT1), TPP1 and the human homolog of yeast RAP1 (RAP1)8. Telomere elongation is
dependent upon the structure of the telomere itself. Longer telomeres attract more
shelterin complexes which maintains the T-loop structure and enhances POT1 binding to
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inhibit telomerase activity, while shorter telomeres surrounded by less shelterin are in a
more open linear configuration that favours the recruitment of telomerase by TPP19.
TERT expression and activity is high in cells undergoing extensive proliferation such as
germ line cells of the testis, embryonic stem cells or malignant cancer cells10. In contrast,
TERT is downregulated in most post-mitotic somatic cells11. Expression of telomerase in
adulthood is generally restricted to cells in highly regenerative tissues, such as
lymphocytes in bone marrow and peripheral blood, epithelial cells in the skin, hair
follicle, intestinal mucosa and endometrium, and adult stem cells12–16.
1.1.2

Telomerase reverse transcriptase (TERT)

Since the reactivation of TERT expression in somatic cells is a key step in cancer cell
transformation, TERT is the most extensively studied telomere-associated protein.
Human TERT (hTERT) is a 127kDa protein encoded by 1132 amino acids and consists
of three main domains: the ~400 amino acid N-terminal region, a central region
containing reverse transcriptase (RT) motifs and the ~200 amino acid C-terminal
region17. The N-terminal region contains the highly conserved GQ motif which is
essential for telomere maintenance, followed by a non-conserved linker sequence which
is proposed to be important for nucleic acid binding, and conserved CP, QFP and T
motifs responsible for binding to TERC18. The RT domain consists of 7 conserved motifs
that contain three critical aspartic acid residues needed for enzymatic activity, termed the
catalytic triad, and regions needed for nuclease activity, nucleotide binding, rNTP/dNTP
discrimination and nucleotide addition18. The C-terminal region is proposed to be
involved in nucleotide addition and processivity18.
1.1.3

Transcriptional/post-translational regulation of TERT

Transcriptional regulation of TERT is important for determining a proliferative or postmitotic phenotype in cells. The ~14kb hTERT gene consists of 16 exons and 15 introns
located on the small arm of chromosome 5 (5p15.33) as a single copy19. Although
expression of full length hTERT is required for telomerase activity, TERT mRNA can be
alternatively spliced to generate α-TERT which contains a deletion in exon 6 and β-
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TERT which has a complete deletion of exon 7 and 820. The hTERT promoter is GC-rich
with a CpG island 330 bp upstream of the ATG start codon21. The hTERT promoter
contains specific domains for transcription factors that promote hTERT expression, such
as two enhancer-boxes (E-boxes) for c-Myc/Myc associated factor X (Max) binding, five
GC-boxes for binding of specificity protein 1 (Sp1) which cooperates with c-Myc, and
estrogen response elements located more than ~950 bp upstream of the ATG22,23. More
importantly, transcriptional repression of hTERT can be regulated by the Max/Max
associated protein D (Mad) complex which competitively binds to E-boxes22. Another
transcriptional repressor of hTERT is the cell cycle arrest and tumor suppressor protein
p53 which interacts with Sp1 to prevent binding to the hTERT promoter24. The
transcription factor E2F-1 can bind to the promoter of hTERT to promote expression,
however this effect can be abolished with the expression of retinoblastoma protein (pRB)
which recruits histone deacetylases to promoter-bound E2F-125. Other repressors of
hTERT transcription is the tumor suppressor Wilms’ tumor 1 (WT1) and myeloidspecific zinc finger protein 2 (MZF-2)26,27. In addition, proteins involved in cell cycle
arrest and differentiation can also inhibit hTERT expression such as interferon alpha
(IFN-α) and transforming growth factor beta (TGF-β). Moreover, certain naturally
occurring or synthetic chemicals such as of vitamin D3, retinoic acid and dimethyl
sulfoxide (DMSO) can repress hTERT expression28–31.
Post translational regulation of hTERT occurs through protein interactions,
phosphorylation, and ubiquitination. The p23 foldasome chaperone binds to the Nterminal region of hTERT and recruits heat shock protein 90 (Hsp90), both of which are
required for assembly of active telomerase with TERC and are the only proteins that
remain associated with active telomerase after assembly32. In addition, human homologs
of the yeast essential telomerase proteins (EST), hEST1A and hEST1B, can bind to
hTERT and contribute to telomere maintenance and protection33. Other proteins shown
to bind to hTERT to enhance telomerase activity are the DNA-PKC interacting protein
KIP which can bind to amino acids 762-855, and Ku which links hTERT with TRF1 and
TRF234,35. A negative regulator of telomerase is the nucleolar TRF1- binding protein
PinX1, which binds to and sequesters hTERT thereby inhibiting interaction with TERC
and preventing activation36. While phosphorylation of hTERT at the N-terminal region
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by proteins such as the alpha isoform of protein kinase C (PKCα) contributes to active
telomerase, phosphorylation by Abelson murine leukemia viral oncoprotein (c-Abl),
phosphatase 2A, and PKCζ proteins inhibit telomerase activity37. The ubiquitin ligase
Makorin Ring Finger Protein 1 (MKRN1) has also been reported to associate with the Cterminal region of hTERT to promote degradation38. Other ubiquitin ligases that can
negatively regulate TERT activity is C terminus of HSC70-Interacting Protein (CHIP)
and Hdm2 (E3 Ligase)39,40.
1.1.4

TERT expression in the brain

TERT activity is generally limited by its restricted expression and is generally
downregulated in most post-mitotic cells. However, TERT has unusual expression
patterns in the brain, irrespective of telomerase activity. Telomerase activity is high
during embryonic and early postnatal development, but declines shortly thereafter and is
undetectable in adult brains41,42. When mouse brain extracts corresponding to the cortex,
hippocampus, and brain stem were examined, telomerase activity peaked in all regions at
embryonic day 13 (E13), declined to low levels by E18, and was undetectable by
postnatal day 10 (P10)43. In contrast, high TERT mRNA levels persist until P5 and low
levels can be detected in the same regions of the adult brain43. By E18 the hippocampus
contains fully differentiated post mitotic neurons and upon further analysis, it was found
that TERT is expressed primarily in hippocampal pyramidal neurons and cortical neurons
but not in astrocytes. In addition, experiments in which TERT expression was either
increased or decreased demonstrated that the protein plays a pivotal role in suppressing
apoptosis induced by trophic factor withdrawal well before mitochondrial dysfunction or
caspase activation44. Since access to trophic factors determines neuronal survival during
development, it has been proposed that TERT regulates synaptic pruning and neuronal
differentiation during early postnatal brain development43,44.
In the adult brain, telomerase activity can be detected in areas with high proliferation,
such as the subventricular zone of the lateral ventricle, a region which contains neural
stem cells45. In addition, TERT expression has been detected in the dentate gyrus of the
hippocampus and the glomeruli, mitral/tufted cell layer, and the olfactory granule cell
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layer of the olfactory bulb, independent of TERC expression46. Interestingly, TERT may
be important for regulating normal brain functions since TERT knock out mice display
altered anxiety-like behaviours and abnormal olfaction46. TERT has also been detected in
the cerebellum, specifically in the nucleus and cytoplasm of Purkinje neurons in adult and
old mice47.

1.2

Non-canonical functions of TERT

1.2.1

Non-canonical functions of TERT in the nucleus

Several studies have suggested that TERT may have functions independent of telomere
extension. TERT overexpression has been reported to promote tumorigenesis by
influencing the expression of genes involved in cell growth and proliferation,
independent of telomere elongation48. Furthermore, downregulating TERT expression
dramatically increases apoptotic cell death well before detectable telomere shortening49.
Studies in TERT-deficient mouse models have revealed that TERT can regulate survival,
tumorigenesis, stem cell properties and gene regulation independent of changes in
telomere length50,51. TERT may also play a critical role in maintaining healthy
mitochondria, as restricting TERT localization exclusively to the nucleus increases
telomeric and extra-telomeric DNA damage, reactive oxygen species (ROS) production
and mitochondrial dysfunction52.
Apart from TERT’s canonical function as a subunit in telomerase, non-canonical
functions of TERT within the nucleus have been reported. Nuclear import of TERT is
dependent on a bipartite nuclear localization signal residing within amino acid residues
222-240 and by phosphorylation on serine 227 by the Akt serine/threonine kinase53.
Another mechanism of nuclear import is through the interaction of nuclear factor kappalight-chain-enhancer of activated B cells (NF-κB) with TERT in the cytosol, which is
recognized by tumor necrosis factor alpha (TNFα) leading to nuclear translocation54. In
the nucleus, NF-κB can induce TERT expression which can then act as a transcriptional
modulator in the NF-κB signaling pathway by binding to p65 and p50 to influence
transcription of NF-κB target genes regulating inflammation and cancer progression55,56.
TERT is also known to bind to the SWI/SNF-related chromatin remodelling protein
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BGR1 to regulate genes involved in proliferation and stem cell renewal via the Wnt/βcatenin signalling pathway57. In addition, TERT may be responsible for the maintenance
of chromatin structure and plays a role in the response to DNA double strand breaks58,59.
Moreover, TERT may participate in telomere capping to stabilize telomeres and increase
lifespan, independent of telomere lengthening60,61.
1.2.2

Properties and functions of mitochondria

Surprisingly, many non-canonical functions of TERT have been reported as a result of its
mitochondrial localization. The mitochondria are cytoplasmic organelles that play a vital
role in maintaining cellular homeostasis and energy production. The structure of this
organelle consists of the mitochondrial matrix surrounded by the inner mitochondrial
membrane (IMM) organized in the form of folds or cristae. The IMM is separated from
the outer mitochondrial membrane (OMM) by the intermembrane space. The
mitochondria has key functions in producing adenosine triphosphate (ATP) and ROS,
initiating apoptosis by releasing proteins that activate caspases, and controlling
intracellular calcium concentrations62.
Also termed the “powerhouse” of the cell, the mitochondria are essential for producing
ATP via oxidative phosphorylation (OXPHOS) to meet cellular energy demands. After
glucose enters the cell via GLUT transporters, it is metabolized to pyruvate through a
series of enzyme catalyzed reactions collectively terms glycolysis63. Pyruvate is actively
shuttled to the mitochondria through mitochondrial pyruvate carriers (MPC), where it is
converted to acetyl coenzyme A (acetyl-CoA) by the enzyme pyruvate dehydrogenase
(PDH) to act as the first substrate within the citric acid cycle (TCA)63. The high-energy
reduced products from the TCA, nicotinamide adenine dinucleotide (NADH) and flavin
adenine dinucleotide (FADH2), are subsequently oxidized in the electron transport chain
(ETC), consisting of five complexes named I-V that are located in the IMM63. The
transfer of electrons through complexes I-V transports protons across the IMM to the
intermembrane space, resulting in a membrane potential across the IMM. The
electrochemical proton gradient across the IMM drives protons back into the matrix
through complex V (ATP synthase), which uses that energy to convert adenosine
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diphosphate (ADP) to ATP63. The entire process produces a net of 34 ATP molecules per
oxidation of one glucose molecule compared to a net of 2 ATP molecules per glucose
molecule produced during glycolysis63. However, complexes I-III can sometimes leak
electrons resulting in the production of oxygen radicals such as superoxide (O2-),
hydroxyl radical (OH-) and hydrogen peroxide (H2O2)64. Low levels of ROS may be
beneficial to the cell, as ROS can be used as a signalling molecule that initiates signalling
cascades important for the redox balance of a cell. Conversely, excessive ROS can lead to
oxidative stress characterized by damage to cell structures, DNA, lipids and proteins65.
Levels of intracellular ROS can be controlled by a variety of antioxidant enzymes such as
catalase, superoxide dismutase (SOD), and glutathione peroxidase (GPx)66.
The mitochondria also play a key role in initiating cell death via the intrinsic apoptosis
pathway. Apoptosis is regulated by the activation of a family of cytosolic caspase
proteases, which cleave cellular contents to initiate programmed cell death67. The
intrinsic pathway of apoptosis relies heavily on mitochondrial components and the
release of cytochrome C, which is a part of the apoptosome complex and can initiate the
activation of caspases68. The anti-apoptotic B-cell lymphoma 2 (Bcl-2) proteins reside in
the OMM and maintain mitochondrial outer membrane permeability (MOMP) to block
cytochrome C release69. However, pro-apoptotic proteins such as Bcl-2-associated X
protein (Bax), which is a subset of proteins from the Bcl-2 family, can translocate from
the cytosol to the mitochondria, undergo oligomerization thereby promoting changes in
MOMP to release cytochrome C from the intermembrane space to the cytosol69. The
translocation of Bax to the mitochondria is considered a key upstream initiator of
intrinsic apoptosis69.
Calcium regulation is another important function of the mitochondria. Calcium acts as a
signalling molecule that has spatially and temporally complex functions, some of which
include roles in metabolism, secretion, muscle contraction, gene expression, and
proliferation70. Typically, the cytosol maintains a very low concentration of Ca2+ with
the aid of Ca2+ pumps and transporters70. The mitochondria can act as a buffer and
respond to Ca2+ influx to the cytosol by providing the rapid removal and storage by
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uptake of excess Ca2+ 70. In neurons, calcium signalling plays a vital role in signal
transmission, excitability, and synaptic plasticity70.
1.2.3

TERT localizes to the mitochondria under oxidative stress

Under normal conditions, approximately 10-20% of the total cellular TERT is localized
to the mitochondria71. However, oxidative stress has been shown to trigger increased
TERT accumulation in the mitochondria; an event linked to mitigation of mitochondrial
dysfunction72,73. Nuclear exclusion occurs in as little as 45 mins after oxidative stress
treatment, reaching a maximum exclusion level of 60% after 24 hours and can persist up
to 5 days, depending on the cell type74. TERT phosphorylation on tyrosine 707 by the
proto-oncogene Src kinase triggers nuclear export by promoting association with GTPbinding nuclear protein Ras-related nuclear protein (Ran GTPase) and the nuclear export
receptor chromosomal maintenance 1/exportin 1 (CRM1/XPO1)75. Alternatively, nuclear
export of TERT can be negatively regulated by the protein tyrosine phosphatase Shp-2,
which is known to antagonize the activities of the Src kinase family76,77. Nuclear export
can also be inhibited by the 14-3-3 signaling protein which interferes with CRM1/XPO1
binding to the nuclear export signal located at the C-terminus of TERT78. After successful
nuclear export, cytosolic TERT is directed to the mitochondria via a mitochondrial
targeting sequence (MTS), which is encoded within the first 20 amino acids79. TERT
interacts with mitochondrial transport protein complexes translocases of the outer
membrane 20/40 (TOM 20/40) and translocase of the inner membrane (TIM23) to cross
the mitochondrial membranes and enter the mitochondrial matrix80,81.
1.2.4

TERT has catalytic activity in the mitochondria

In the mitochondria, TERT can have reverse transcriptase activity even in the absence of
TERC. TERT interacts with mitochondrial tRNAs to synthesize cDNA, suggesting a role
in mitochondrial DNA (mtDNA) replication or repair71. Conversely, TERT has been
shown to have a novel RNA-dependent RNA polymerase (RdRP) activity that is
independent of its DNA reverse transcriptase function, and is the only RdRP identified in
mammals82. TERT forms a complex with the mitochondrial RNA processing
endoribonulease (RMRP) and is able to produce siRNAs from double-stranded RNAs,
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which can influence transcriptional or post-transcriptional gene silencing of the RMRP
gene82.
1.2.5

TERT prevents mitochondrial dysfunction under oxidative stress conditions

Recent studies have demonstrated that mitochondrial localization of TERT contributes to
the proliferative and survival properties of cancer cells79,83. Under oxidative stress
conditions, TERT prevents mtDNA oxidative damage and degradation, decreases
mitochondrial superoxide production and ROS levels and maintains a high mitochondrial
membrane potential73,74,77,80,81. These effects on mitochondrial function may indirectly
protect against nuclear DNA damage and apoptosis in response to oxidative stress74,80. A
possible mechanism for TERT-mediated reduction in ROS production and suppression of
apoptosis is by decreasing ROS-induced cytosolic acidification and blocking
translocation of Bax to the mitochondria, which is critical for pro-apoptotic signalling81.
TERT plays a central role in cell viability through regulation of intrinsic mitochondrialinduced apoptosis, which makes it an attractive target for cancer therapeutics84. While
some studies have shown that TERT catalytic activity in conjunction with TERC
expression may be essential for suppression of apoptosis, overexpression of an
catalytically inactive form of TERT has been shown to inhibit Bcl-2 and p53 dependent
apoptosis85–87. In addition, TERT inhibition via siRNA sensitizes cells to the activation of
Bax and subsequent apoptosis88. Downregulation of TERT results in activation of the
JNK/p38-MAPK pathway and increased cleavage of caspase 3, 8 and 9, which are
involved in mitochondrial induced apoptosis89,90. Downregulation of TERT is also
associated with an increase of cytosolic cytochrome C due to disrupted mitochondrial
membrane potential91.
TERT overexpression reduces basal ROS levels and overall ROS production during
oxidative stress conditions81. This may be accomplished through improving respiratory
chain activity or antioxidant activity. Mitochondrial TERT reduces succinate-linked
respiration and decreases complex I activity, both of which contribute to mitochondrial
ROS production80. TERT can bind to mtDNA at coding sequences for NADH:ubiquinone
oxidoreductase (complex I) subunit 1 and 2 (ND1 and ND2), which is thought to increase
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synthesis of these subunits and allow for replacement of subunits damaged by ROS
production80. Furthermore, TERT overexpressing cells improve mitochondrial function
by limiting levels of the uncoupling protein uncoupling protein 2 (UCP2), which is
transcriptionally upregulated by high ROS levels73. TERT can also affect the production
and availability of various antioxidants to reduce ROS production. TERT overexpressing
cells have a higher reduced glutathione compared to oxidized glutathione, which is an
important co-factor for GPx activity81. It was also observed that TERT overexpressing
cells upregulate glutamate cysteine ligase (GCL), the enzyme needed for the production
of glutathione and exhibit a more rapid recovery of peroxiredoxin isoforms from their
hyperoxidized state81. Moreover, TERT overexpressing cells exhibit increased complex
IV activity, which contributes to the electrochemical proton gradient utilized by ATP
synthase (complex V) for ATP production81.
1.2.6

Mitochondrial localization of TERT is neuroprotective

Mitochondrial localization of TERT may also benefit neurons due to its anti-apoptotic
functions, implicating a vital role in aging and neurodegenerative disease. Specifically in
brain tissue, dietary restriction or inhibitors of the mechanistic target of rapamycin
(mTOR) pathway decreases ROS production, but this is dependent on an increase of
TERT transcription and protein localization to the mitochondria92. In cerebellar Purkinje
neurons, neuronal stressors such as glutamate excitotoxicity increases mitochondrial
TERT localization93.
Primary neuronal cultures derived from transgenic mice overexpressing TERT have
increased neuronal survival following N-methyl-D-aspartate (NMDA) exposure
compared to neuronal cultures from control mice94–96. This increase in cell survival may
occur due to TERT mediated effects on mitochondrial membrane potential and
mitochondrial uptake of Ca2+, thereby decreasing the accumulation of cytosolic free
calcium Ca2+ after NMDA receptor activation94. In addition, TERT was detected in the
cytosol and nucleus of microglia up to 7 days after excessive stimulation of NMDA
receptors by the seizure-inducing drug kainite97.
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TERT is also protective against initiators of apoptosis in neurons following exposure to
various forms of stress. TERT inhibition in cultured neurons that are deprived of oxygen
and glucose results in increased caspase 3 cleavage, decreased Bcl-2/Bax expression,
enhanced ROS production, and reduced mitochondrial membrane potential98. In a
transgenic mouse model of amyotrophic lateral sclerosis (ALS), increased TERT
expression protected against spinal cord motor neuron death96. Neuroprotection is
believed to be mediated, in part, by tropomyosin receptor kinase B (TrkB) induced
signalling of brain derived neurotrophic factor (BDNF) which can upregulate
transcription factors c-Myc, Sp1 and NF-κB, thereby increasing TERT expression and
telomerase activity in spinal cord motor neurons undergoing injury99. This confers
resistance to apoptosis mediated through Bcl-2, Bax, p53 and a maintenance of
mitochondrial membrane potential99. Another study has shown that in hippocampal
neurons, TERT localizes to cytosolic RNA granules100. Within the RNA granules, TERT
colocalizes with p15INK4B mRNA, which is known to promote cell cycle arrest by
inhibition of cyclin-dependent kinases CDK4 and CDK6100. Upon acute stress, TERT
disassociates from the P15INK4B mRNA allowing for translation, suggesting this may be
a mechanism for TERT’s pro-survival effect in neurons100.
There is also evidence that TERT may contribute to the protective roles in cell types
other than neurons in the brain after tissue injury. After permanent ischemic damage,
TERT mRNA is rapidly increased within 4 hours in the cytoplasm of surviving ipsilateral
cortical neurons94. However, a separate study showed that TERT protein expression
shifts from neurons to astrocytes after 3 days in a hypoxic-ischemic rat model101.
Transient ischemic brain injury also induced increased TERT mRNA expression in
astrocytes in the uninjured ipsilateral hemisphere102. TERT expression in astrocytes
corresponds with an upregulation of the cell cycle regulator p15 to inhibit proliferation of
reactive astrocytes and the increased expression of neural growth factor neurotrophin-3
(NT-3) to promote neuronal survival101.

1.3

Alzheimer’s Disease and TERT

1.3.1

Alzheimer’s Disease and oxidative stress
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Alzheimer’s disease (AD) is the most prevalent form of dementia worldwide. It is
characterized by the deposition of intracellular neurofibrillary tangles composed of
hyper-phosphorylated tau protein and extracellular plaques composed of amyloid-beta
(Aβ) peptides103. Early-onset AD occurs in 1%-6% of cases and is most commonly the
result of a mutation in the amyloid precursor protein (APP) or the secretases (PSEN1,
PSEN2) that shift the processing of the APP to the pathogenic 1-42 amino acid Aβ
peptide (Aβ1-42)104. This Aβ1-42 peptide can spontaneously aggregate into soluble
oligomers, and further accumulate to form insoluble beta-sheet fibrils, finally forming
deposits of diffuse or compact plaques105. Over time, there is progressive degeneration of
neurons and synapses in areas of the brain involved in memory and cognition such as the
hippocampus, entorhinal cortex, and basal forebrain106.
Mitochondrial dysfunction and oxidative stress are prominent features of many
neurodegenerative diseases107. A neuron’s high energy demand makes it reliant on
mitochondrial oxidative phosphorylation to produce ATP, which is more efficient at ATP
production than glycolysis108. However, due to the high number of neuronal mitochondria
and the relatively low levels of antioxidant enzymes compared to other organs, neurons
are especially vulnerable to ROS109. Aging can lead to increased mitochondrial DNA
mutations and damaged complexes in the ETC, leading to elevated electron leakage and
reduced ATP synthesis63. It has also been reported that patients with AD have altered
mitochondrial morphology, reduced cytochrome c oxidase (complex IV) activity and
reduced activity of enzymes within the TCA cycle62,110. In addition, glycolysis is
perturbed as evidenced by lower levels of glucose transporters (GLUT1 and GLUT3) and
enzymes involved in glycolysis (phosphofructokinase (PFK), glucose6-phosphate
isomerase and lactate dehydrogenase in the brains of AD patients compared to age
matched controls111,112. A decrease in glucose consumption and oxygen metabolic rates
are observed during normal aging, but this effect is further exacerbated during
neurodegenerative disease, such as AD113.
In AD, oxidative damage occurs well before Aβ plaque accumulation and is believed to
be a major contributor to pathogenesis114. Recent studies suggest that neuronal
dysfunction and degeneration is due to the accumulation of intracellular Aβ, which
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eventually causes lysis of the cell leading to extracellular Aβ plaque deposition115,116. The
Aβ1-42 oligomers have been shown to be toxic to neurons, synapses and the mitochondria
by promoting ROS production, oxidative damage, and tau phosphorylation117,118. Aβ1-42
oligomers directly interfere with mitochondrial function via Aβ binding alcohol
dehydrogenase (ABAD) resulting in mitochondrial impairment, ROS production, and cell
death119. In addition, transgenic mice that express mutant human APP reveal decreased
basal levels of mitochondrial membrane potential at 3 months of age compared to
littermate controls109. At this time, only moderately elevated intracellular Aβ load is
detected, suggesting that Aβ production interferes with mitochondrial function well
before Aβ plaque deposition109. Since current insights of AD pathology propose there is a
cyclic relationship between oxidative damage and Aβ production, it may be useful to
investigate targets that reduce the damaging effects of oxidative stress62. Recently, it has
been proposed that lifestyle factors such as dietary restriction, intellectual activity and
exercise may target intrinsic biological mechanisms to limit oxidative damage120,121.
Surprisingly, amyloid-deposition is observed in about 25% of cognitively normal elderly
individuals122. Investigation of Aβ resistant cells reveal an upregulation of antioxidant
enzymes such as peroxiredoxin 1 (Prx1), GPx and catalase. In addition, Aβ resistant cells
exhibit an increase in glucose uptake and glycolysis due to an activation of transcription
factor hypoxia inducible factor 1 (HIF-1)123–125. Increased activation of the alpha subunit
of HIF-1 (HIF-1α) is frequently observed in tumors resulting in an increase of glucose
uptake and lactate production, even in the presence of oxygen126. This phenotype is
termed the Warburg effect or aerobic glycolysis. In vitro studies of Aβ resistant cells
demonstrate that elevated aerobic glycolysis is a neuroprotective mechanism that
decreases mitochondrial ROS production and increases resistance to Aβ -induced
apoptosis127. Furthermore, increased expression of rate-limiting enzymes in aerobic
glycolysis, such as lactate dehydrogenase (LDHA) or pyruvate dehydrogenase kinase 1
(PDK1), can protect against Aβ toxicity128. Positron emission tomography (PET) imaging
of AD patients demonstrated that aerobic glycolysis correlates spatially in individuals
that have high Aβ plaque deposition but are cognitively normal129. Altogether, these
results suggest that neurons may become resistant to the toxic effects of Aβ by altering
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their metabolism, moving away from OXPHOS and towards aerobic glycolysis for their
energy needs.
1.3.2

TERT is protective against amyloid-beta

Telomere shortening and a decrease in TERT expression occurs significantly more in
hippocampal neurons of AD patients compared to aged matched controls130. Recent in
vitro studies demonstrate that increasing TERT expression and activity may be beneficial
against Aβ toxicity. One study showed that estrogen receptor activation is
neuroprotective against Aβ toxicity in a manner dependent on upregulation of TERT
activity131. A proposed mechanism is through activation of TERT via phosphorylation by
Akt kinase, causing TERT to associate with NF-κB and translocate to the nucleus where
telomerase activity can occur131. A separate study determined that treating primary
murine cerebrovascular endothelial cells with calf serum was able to reverse Aβinhibition of HSP90 expression, a protein which binds to TERT, and facilitate an
upregulation of telomerase activity to prevent apoptosis induced by Aβ132. Similarly,
TERT may protect mouse hippocampal neurons from Aβ induced apoptosis by limiting
mitochondrial ROS production and by maintaining mitochondrial membrane potential133.
Interestingly, the vaccine peptide GV1001 derived from the TERT sequence blocks Aβ
toxicity by localizing to the mitochondria of rat neural stem cells and reduces ROS levels,
mitochondrial DNA damage, and alters expression levels of survival/death related
proteins to prevent apoptosis134. More recently, in vivo studies in mice have confirmed
that while TERT is expressed in both aged control and transgenic AD adult hippocampal
neurons, the organelle localization of TERT differed between these two groups132.
Mitochondrial localization of TERT was observed in transgenic AD brains and the
presence of TERT was mutually exclusive from hyper-phosphorylated tau, suggesting a
neuroprotective function against tau pathology135.

1.4

Rationale

The current field of research has recognized many physiological functions of TERT apart
from its canonical role in maintaining telomeres. Most importantly, it has been shown
that mitochondrial localized TERT protects against oxidative stress and the toxic effects
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of the Aβ, a peptide strongly implicated in AD pathogenesis. In addition, Aβ resistant
cells have been known to switch their metabolism to aerobic glycolysis through a
mechanism which is poorly defined. I hypothesize that TERT will localize to the
mitochondria and alters metabolism in a manner which renders neurons less
susceptible to toxicity following exposure to Aβ or oxidants. As a result of
mitochondrial localization of TERT, mitochondrial ROS levels will lower and cell
viability will increase in Aβ challenged cells. Since mitochondrial dysfunction is a
prominent feature of AD, the discovery of mitochondrial associated functions of TERT
may implicate TERT as a potential therapeutic target for AD and other neurodegenerative
diseases.
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Chapter 2: Materials and Methods
2.1

Plasmids

Human TERT (072-hTERT, referred to as TERT) and 071-FLAG-hTERT (referred to as
FLAG-TERT) cDNA expression plasmids were generously provided by Dr. Lea
Harrington (IRIC, Montreal, Quebec, Canada). The pcDNA 3.1 plasmid (referred to as
pcDNA; Invitrogen) was used as a transfection control in all experiments. The pcDNA3EGFP plasmid (referred to as GFP; Addgene) was used as a transfection control for
MitoTracker CMXROS experiments. Transfection efficiency was between 40-50%,
which was assessed following co-transfection of the TERT plasmid with GFP and
visualization by fluorescence microscopy.

2.2

Cell Culture

The HT22 immortalized mouse hippocampal neuronal cell line was a gift from Dr. Dave
Schubert (Salk Institute for Biological Sciences, California, USA). HT22 cell cultures
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza)
supplemented with 10% Fetal Bovine Serum (FBS) (Corning) and 1%
penicillin/streptomycin (P/S) (Gibco). Cells were cultured in an incubator at 37°C and
5% CO2.

2.3

Aβ Preparation

Aβ(25-35) was purchased from California Peptide and dissolved in sterile ddH2O to a
concentration of 1 mM then left overnight at room temperature to allow fibril formation
before storing at -20°C, as previously described127.

2.4

Western Blot

HT22 cells were seeded at 150 000 cells per 60 mm cell culture dish and grown to 50%70% confluency then transfected with 3 µg DNA (TERT, pcDNA) using 1 mL OptiMEM (Gibco) and 5 µL Lipofectamine 2000 (Invitrogen) according to manufacturer’s
instructions. Transfection media was replaced with DMEM + 10% FBS + 1% P/S media
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after 5 hours and the cell cultures recovered overnight. The following day cell cultures
were treated for 4 hours with 400 µM H2O2 (Sigma) or 25 µM Aβ25-35 (California
Peptide),then washed twice in Phosphate Buffer Saline (PBS; Lonza) and lysed in icecold RIPA buffer (10 mM Tris-Hcl pH 8, 1% Triton X-100 (Sigma), 0.1% Sodium
deoxycholate, 0.5 mM EGTA, 0.1% SDS, 140 mM NaCl) containing a protease inhibitor
cocktail (2 mM leupeptin (Sigma), 0.1 mM pepstatin A (Sigma)), phenolmethanesulfonyl
fluoride (Sigma), and sodium orthovanadate (Sigma). Protein content from whole cell
lysate was quantified using the DC protein assay (Bio-Rad). Protein samples were
resolved by 10% SDS-PAGE, immunoblotted onto polyvinylidene fluoride membrane
(Bio-Rad), and blocked in TBS-T buffer containing 3% BSA (VWR), 1% non-fat dry
milk (Cell Signalling). Blots were hybridized with the following primary antibodies: antihTERT (600-401-252S; Rockland), anti-PDH (ab110334; abcam), anti-Actin (sc-47778;
Santa Cruz), anti-pser232 PDH (AP1063; EMD Millipore), anti-LDHA (#2012; Cell
Signalling), anti-PDK1 (ADI-KAP-PK112-F; Enzo Life Sciences), anti-PKM1 (#7067;
Cell Signalling), and anti-PKM2 (#3198; Cell Signalling). Following incubation with
HRP-conjugated secondary mouse (sc-2005; Santa Cruz) and rabbit (sc-2030; Santa
Cruz) antibodies, blots were visualized by enhanced chemiluminescence using the
Luminata Forte substrate (EMD Millipore) and imaged in a Chemidoc XRS System (BioRad). Densitometric quantification of band intensity of three independent experiments
was performed using Image Lab software (Bio-Rad).

2.5

MitoTracker Red CMXROS

To determine mitochondrial ROS levels of the cells, the fluorescent dye MitoTracker Red
CMXRos (Life Technologies) was used. HT22 cells were seeded at 80, 000 cells per 35
mm cell culture dish and grown to 50%-70% confluency. The cell cultures were
transfected with 1.2 µg DNA (TERT/pcDNA:GFP, 2:1 ratio) and 2 µL Lipofectamine
2000 in 800 µL Opti-MEM according to manufacturer’s instructions. Transfection media
was replaced with DMEM + 10% FBS + 1% P/S media after 5 hours. The following day,
cell cultures were treated for 12 hours with 400 µM H2O2 or 25 µM Aβ25-35. After
treatment, the cell cultures were incubated at 37°C for 20 minutes with phenol-red free
DMEM + 10% FBS + 1% P/S containing 200 nM MitoTracker Red CMXRos. Cells were
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washed twice with PBS and incubated with 10 ug/mL Hoeschst (Life Technologies) in
PBS for 1 minute at room temperature. Cells were rinsed with PBS, placed in phenol-red
free DMEM + 10% FBS + 1% P/S and analyzed by fluorescence microscopy using a
Leica DMI6000 B microscope equipped with an ORCA Hamamatsu digital camera. All
digital images were captured at the same exposure time and analyzed using ImageJ
software (National Institute of Health). The mean red fluorescence of three images per
treatment was calculated for each of three independent experiments.

2.6

Cell Viability Assay

The MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay was
used to assess cell viability. 150 000 HT22 cells were seeded in a 60 mm cell culture dish
and grown to 50%-70% confluency. Cell cultures were transfected with 3 µg DNA
(TERT, pcDNA) and 5 µL Lipofectamine 2000 in 1 mL Opti-MEM according to
manufacturer’s directions. Transfection media was replaced with DMEM + 10% FBS +
1% P/S media after 5 hours and the next morning, cells were trypsinized and 7 000 cells
per well were seeded in a 96-well plate with DMEM + 10% FBS + 1% P/S media. After
cell adherence (approx. 5 hours), the cells were treated for 24 hours with DMEM + 5%
FBS + 1% P/S media containing 400 µM H2O2 or 25 µM Aβ25-35. The concentration of
Aβ was chosen based on previous studies127 whereas the H2O2 concentration was
determined following a dose response curve (see Appendix 5). Live cells were visualized
and representative images were taken for each treatment using a Leica DMIL LED phase
contract microscope. Then the media was replaced with DMEM + 5% FBS + 1% P/S
media with MTT reagent (Sigma) added at a final concentration of 10%. Culture plates
were incubated at 37°C for 3 hours. After incubation, culture medium containing MTT
was aspirated, replaced with DMSO and the optical density was measured at 595 nm
using a microplate reader (Bio-Rad Model 3550). All treatments were seeded in
triplicates and the mean viability was calculated from three independent experiments.

2.7

Immunofluorescence

Cover slips were placed in a 6-well plate and treated with 50 µg/mL Poly-D lysine
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(Sigma) overnight. After washing with sterile water, 60 000 HT22 cells per well were
seeded and grown to 50% confluency. Cell cultures were transfected with 1.2 µg DNA
(FLAG-TERT, pcDNA) 2 µL Lipofectamine 2000 (Invitrogen) in 800 µL Opti-MEM
according to manufacturer’s instructions. Transfection media was replaced with DMEM
+ 10% FBS + 1% P/S media after 5 hours and the next morning, cells were treated for 12
hours with 400 µM H2O2 or 25 µM Aβ25-35. Cells that adhered onto cover slips were
transferred to a 12-well cell culture plate, washed twice with PBS and fixed with ice cold
4% paraformaldehyde in PBS for 10 minutes at room temperature. Cells were washed
once with PBS and then twice with PBS + 1% Triton X-100 before blocking with 3%
goat serum (Invitrogen) in PBS + 1% Triton-X-100 for 1 hour at room temperature. Fixed
cells were hybridized with the primary antibodies anti-FLAG (F3165; Sigma) and antiTOM20 (sc-11415; Santa Cruz) diluted 1:200 in in 3% goat serum in PBS + 1% TritonX. Following an overnight incubation at 4°C, coverslips were washed twice with PBS +
1% Triton-X followed by hybridization with anti-mouse IgG secondary antibody
conjugated to Alexa Fluor 488 (Invitrogen) and goat anti-rabbit IgG secondary antibody,
Alexa Fluor 594 (Invitrogen) diluted 1:200 in 3% goat serum in PBS + 1% Triton-X for 1
hour at room temperature. Cover slips were then washed twice with PBS + 1% Triton-X
and then mounted on a glass slide using ProLong Gold Antifade Mountant with DAPI
(Invitrogen). Clear nail polish was used to seal the edges. Slides were visualized by
fluorescence microscopy using the Leica DMI6000 B equipped with an ORCA
Hamamatsu digital camera. Images were captured at the same exposure time for all
treatments.

2.8

Statistical Analysis

Data are presented as means ± SD resulting from three independent experiments. Data
were analyzed statistically using a one-way ANOVA followed by a Tukey test (GraphPad
software). Results were considered statistically significant at p≤0.05.
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Chapter 3: Results
3.1

TERT partially localizes with mitochondria following H2O2 or
Aβ exposure

Previous studies have shown that TERT localizes to mitochondria under oxidative
conditions136–138 . Due to low expression of endogenous TERT and the lack of anti-TERT
antibodies suitable for immunofluorescence staining, HT22 cells were transfected with a
FLAG-TERT plasmid to allow the use of an anti-FLAG antibody to detect overexpressed
TERT. Cells were then treated with 400 µM H2O2 and 25 µM Aβ25-35 for 12 hours and
co-staining was performed using anti-FLAG and anti-TOM20 (mitochondrial marker)
antibodies. DAPI was used as a nuclear marker. Under control conditions, TERT
expression is primarily nuclear, as illustrated by colocalization of FLAG (green) with
DAPI (blue) (Figure 1A). However, after 12 hours of oxidative stress induced by 400 µM
H2O2 and 25 µM Aβ25-35 exposure, there are two patterns of TERT localization that
emerge (Figure 1B,C). The first is characterized by reduced localization of TERT from
the nucleus and increased localization to mitochondria. The second pattern shows TERT
is present in both the nucleus and the mitochondria. Both patterns illustrate that TERT
may have non-canonical mitochondrial functions under oxidative stress conditions.

Control

C

25 µM Aβ

400 µM H2O2

B

A

TOM20 + DAPI

20 µm

20 µm

20 µm

FLAG-TERT

20 µm

20 µm

20 µm

Merge

Immunofluorescence staining of HT22 cells transfected with a FLAG-TERT expression construct. Cells were exposed to
H2O2 (400 µM) or Aβ25-35 (25 µM) for 12 hours post-transfection and stained with anti-FLAG and anti-TOM20 antibodies.
(A) TERT localizes to the nucleus under control conditions. (B) White arrows indicate partial co-localization of TERT with
the mitochondrial marker TOM20 occurred after 400 µM H2O2 and (C) 25 µM Aβ exposure. Green (FLAG-TERT), Red
(TOM20), blue (DAPI). 40X objective lens. Scale bars are 20 µm.

Figure 1: TERT partially localizes to the mitochondria following H2O2 or Aβ exposure.
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3.2

TERT expression promotes a shift towards glycolysis under
oxidative stress

To assess the effect of TERT expression on metabolic enzyme levels, HT22 cells were
transfected with TERT or pcDNA plasmids, followed by a 4 hour exposure to low and
high concentrations of H2O2 (100 µM, 400 µM) and 25 µM Aβ25-35. No toxicity was
observed following a four hour exposure to these stressors (data not shown). Protein
levels of enzymes involved in metabolism were assessed via Western blotting (Figure
2A). Pyruvate dehydrogenase (PDH) is the rate-limiting enzyme that catalyzes the
conversion of pyruvate to acetyl-CoA to fuel the TCA cycle. Increased phosphorylation
of PDH at serine 232 by pyruvate dehydrogenase kinase 1 (PDK1) restricts OXPHOS by
rendering PDH inactive, resulting in a metabolic shift towards glycolysis to satisfy the
cell’s energy requirements. TERT transfected cells had elevated levels of phosphoPDH/total PDH and PDK1 when stressed with 100 µM H2O2, 400 µM H2O2 and 25 µM
Aβ25-35 (Figure 2B), indicative of less OXPHOS. Another important enzyme involved in
glycolytic metabolism is lactate dehydrogenase A (LDHA). LDHA catalyzes the
conversion of pyruvate to L-lactate while oxidizing NADH to NAD+ as a by-product.
TERT transfected cells had elevated levels of LDHA when stressed with 100 µM H2O2,
400 µM H2O2 and 25 µM Aβ25-35 (Figure 2B), indicative of enhanced glycolytic
metabolism. Finally, the levels of alternatively spliced M1 and M2 isoforms of pyruvate
kinase (PK) were quantified. PK catalyzes the irreversible reaction between
phosphoenolpyruvate (PEP) and ADP to produce pyruvate and ATP in the last step of
glycolysis. While PKM1 is constitutively active, the dimeric form of PKM2 is expressed
in tissues with high anabolic functions, such as cancer cells, and has a low affinity for
PEP139. This results in the accumulation of glycolytic intermediates, which enter the
glycerol synthesis and pentose phosphate pathways (PPP), limiting the production of
pyruvate to fuel OXPHOS139. A decrease in the ratio of PKM1/PKM2 enzymes was
observed in TERT transfected cells when stressed with 100 µM H2O2, 400 µM H2O2 and
25 µM Aβ25-35 (Figure 2B), indicating higher PKM2 levels. Altogether, TERT
overexpressing cells demonstrate a shift towards glycolytic metabolism by altering
protein levels of metabolic enzymes.
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Figure 2B

Figure 2: Immunoblot analysis of metabolic markers reveals a shift towards glycolysis
in TERT expressing cells following H2O2 and Aβ exposure.
(A) HT22 cells were transfected with pcDNA or TERT plasmids followed by a 4 hour
exposure to H2O2 (100 µM, 400 µM) or Aβ25-35 (25 µM). Protein levels of metabolic
enzymes (phospho-PDH/total PDH, PDK1, LDHA, PKM1/PKM2) were assessed by
immunoblot analysis with the indicated antibodies. (B) Densitometric analysis of band
intensity revealed significantly higher levels of phospho-PDH/PDH, PDK1 and LDHA and a
lower protein ratio of PKM1/PKM2 in the TERT transfected cells compared to controls after
oxidative stress treatments (100 µM H2O2, 400 µM H2O2, 25 µM Aβ25-35). The data
presented are from three independent experiments ± SEM. Asterisk indicates significant
difference (*, p≤ 0.05; **, p≤ 0.01; ***, p≤ 0.001; ****, p≤ 0.0001) tested by One-Way
ANOVA followed by a Tukey test.
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3.3

TERT expression prevents increases in mitochondrial ROS
under oxidative stress

Since the TERT overexpression plasmid did not have a fluorescent tag, cell cultures were
co-transfected with a GFP plasmid at a 2:1 ratio (TERT:GFP) in order to identify
transfected cells. It is presumed that cells with green fluorescence (GFP) will also contain
the TERT overexpressing plasmid. HT22 cells were co-transfected with TERT + GFP
and pcDNA + GFP plasmids, followed by a 12 hour exposure to 400 µM H2O2 or 25 µM
Aβ25-35. Transfected cells were stained with MitoTracker Red CMXROS, a mitochondrial
localized dye that emits red fluorescence in proportion to mitochondrial ROS levels, and
visualized by fluorescence microscopy (Figure 3A,B). MitoTracker Red CMXROS
fluorescence intensity of GFP positive cells was analyzed to determine differences
between treatments (Figure 3C). Under control conditions, pcDNA and TERT transfected
cells had comparable levels of ROS. However, when cells were exposed to 25 µM Aβ2535,

TERT transfected cells had significantly lower levels of ROS compared to pcDNA

transfected cells. Therefore, under oxidative stress conditions elicited by Aβ25-35
exposure, cells overexpressing TERT have lower mitochondrial ROS levels.
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Figure 3A
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Figure 3B
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Figure 3C

Figure 3: TERT overexpression reduces mitochondrial ROS levels following Aβ
exposure.
HT22 cells were co-transfected with GFP along with pcDNA or TERT plasmids
followed by a 12-hour exposure to H2O2 (400 µM) or Aβ25-35 (25 µM). TERT
transfected cells were stained with MitoTracker Red CMXROS and visualized by
fluorescence microscopy. Red (MitoTracker CMXROS), blue (Hoescht), white arrows
(GFP positive cells). Representative photomicrographs of pcDNA (A) and TERT
transfected cells (B). (C) Fluorescence intensity of GFP positive cells was quantified
using Image J software. TERT overexpressing cells have a reduction in ROS levels
under 400 µM H2O2 treatment and a significant reduction in ROS levels under 25 µM
Aβ25-35 treatment compared to pcDNA transfected cells. The data presented are from
three independent experiments ± SEM. Asterisk indicates significant difference (**,
p≤0.01) tested by One-Way ANOVA followed by a Tukey test. Scale bars are 20 µm.
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3.4

TERT overexpression promotes increased cell viability during
oxidative stress

HT22 cells were transfected with TERT or pcDNA plasmids, followed by a 24 hour
exposure to 400 µM H2O2 or 25 µM Aβ25-35. Live cells were visualized by phase contrast
microscopy (Figure 4A). When cells were cultured under control conditions, TERT
transfected cells had a higher confluency compared to pcDNA transfected cells. When
stressed with 400 µM H2O2 or 25 µM Aβ25-35, TERT transfected cells maintained healthy
morphology characterized by neuronal-like elongated processes protruding from the cell
body. In contrast, increased cellular debris and morphologically stressed cells
characterized by shrunken processes and rounding was observed in oxidant challenged
pcDNA transfected cells. The MTT cell viability assay revealed that TERT transfected
cells had significantly more cell viability under control and oxidative stress conditions
compared to pcDNA transfected cells (Figure 4B). These results confirm that TERT
confers a survival advantage following oxidative stress induced by H2O2 or Aβ exposure.
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Figure 4B

Figure 4: TERT confers a cell survivability advantage under H2O2 and Aβ induced
stress.
(A) Representative photomicrographs (200X magnification) of HT22 cells transfected with
pcDNA or TERT plasmids followed by a 24 hour exposure to H2O2 (400 µM) or Aβ25-35 (25
µM). (B) Cell viability was assessed using the MTT assay. TERT overexpressing cells had
significantly higher cell viability under control, 400 µM H2O2 and 25 µM Aβ25-35
treatments. The data presented are from three independent experiments ± SEM. Asterisk
indicates significant difference (*, p≤0.05; **, p≤0.01) tested by One-Way ANOVA
followed by a Tukey test. Scale bars are 50 µm.
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Chapter 4: Discussion
The present study provides evidence that TERT partially localizes to the mitochondria
under H2O2 and Aβ-induced oxidative stress and alters metabolism in favour of
glycolysis. By limiting mitochondrial metabolism, ROS production is significantly
reduced and cell viability is improved. TERT promotes a shift towards glycolysis within
the first 4 hours of oxidative stress exposure, which is supported by changes in
expression of metabolic enzymes such as an increase in the phospho-PDH/total PDH
ratio, elevated levels of PDK1 and LDHA, and a decrease in the PKM1/PKM2 ratio. This
is the first demonstration that TERT expression can promote altered levels of glycolytic
enzymes during oxidative stress. Up to 12 hours later, TERT overexpressing cells have
decreased mitochondrial ROS production and have greater cell survivability at 24 hours
after oxidative stress treatment compared to controls. These results indicate that aerobic
glycolysis may be an important feature for TERT’s protective effects against oxidative
stress. As previously discussed, elevated aerobic glycolysis allows neurons to become
resistant to Aβ toxicity. This study offers evidence of a novel pro-survival mechanism
mediated by TERT involving upregulation of aerobic glycolysis enzymes and a
concomitant reduction of mitochondrial ROS production. A proposed mechanism is
outlined in Figure 5.

4.1

HT22 cell culture is an appropriate model to study AD

The HT22 cell line is an immortalized mouse hippocampal neuronal cell line, developed
from HT4 cells that were originally immortalized from primary mouse hippocampal
neuronal cultures140. AD patients experience severe neurodegeneration and a decrease of
volume of the hippocampus, which has critical functions in learning and memory141. The
HT22 cell cultures recapitulate features of hippocampal neurons such as expression of
cholinergic markers and glutamate sensitivity142,143. In addition, HT22 cells have been
used extensively as a neuronal model to study oxidative stress induced by glutamate and
H2O2 exposure144–148. Furthermore, Aβ induced oxidative stress in HT22 cells has been
previously used as a model to study neurotoxicity in Alzheimer’s disease149–153. However,
there are some limitations of using an immortalized cell line to study the function of

33

neurons. HT22 cells are rapidly dividing cells that have a doubling time of approximately
15 hours which may subject the cells to genetic drift as the cells divide, whereas neurons
in the brain are post-mitotic. In addition, the brain is a complex structure consisting of
various cell types, such as astrocytes and glia, and molecules that can act on neurons,
such as neurotransmitters, which makes the physiology of neurons in the brain different
from HT22 cell cultures. Future studies should use primary neuronal culture as a more
physiologically relevant model to determine the protective effects of TERT.
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Figure 5
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Figure 5: Proposed mechanism of TERT mediated induction of aerobic glycolysis
and protection from Aβ toxicity.
Aβ can promote increased mitochondrial ROS by either activating p66Shc or directly
interfering with the electron transport chain (ETC). Elevated aerobic glycolysis confers
protection from Aβ toxicity by reducing mitochondrial respiration while increasing the
pentose phosphate pathway (PPP) with a resulting increase in antioxidant activity. An
increase in aerobic glycolysis enzymes including PDK1, phospho-PDH/PDH and LDHA
along with a decrease in PKM1/PKM2 protein levels was observed in TERT transfected
cells exposed to Aβ. HIF1-α is known to promote aerobic glycolysis by increasing
expression of the same metabolic enzymes induced by TERT expression. Hence, it is
proposed that TERT may activate HIF1-α in the nucleus, or TERT may translocate to the
mitochondria and bind to ND1 and ND2 coding regions which activates HIF1-α and
prevents oxidative stress-induced damage. Alternatively, TERT may prevent activation of
p66shc through JNK, or may directly interact with P-p66Shc in the mitochondria to
prevent mitochondrial dysfunction.

36

4.2

TERT has partial localization to the mitochondria

Immunofluorescence experiments illustrated that TERT localizes to the nucleus under
control conditions and has partial localization with the mitochondria after 12 hours of 400
µM H2O2 and 25 µM Aβ treatments. This is in agreement with previous studies that
identified TERT expression in cultured hippocampal neurons as well as in control adult
human hippocampal neurons46,135. Mitochondrial localization of TERT has also been
previously confirmed under different cell types exposed to H2O2 stress and in
hippocampal neurons derived from AD brains73,80,83,135,154. However contrary to previous
research, the current study demonstrated that TERT is not completely excluded from the
nucleus in the cells that exhibit mitochondrial localization. This effect may be due to the
use of the FLAG-TERT plasmid that contains the FLAG epitope at the N-terminus of the
TERT coding sequence, which may interfere with mitochondrial targeting and import of
TERT.
It has previously been determined that TERT has a maximum exclusion level of 60%
from the nucleus after 24 hours in cancer cells154. Although it is suggested that oxidative
stress promotes translocation of existing nuclear TERT to the mitochondria, this study
does not address the possibility of cytosolic TERT that bypasses nuclear localization and
is directly targeted to the mitochondria instead. Future studies should quantify FLAGTERT co-localization patterns in HT22 cells to determine if there is significant
mitochondrial localization following H2O2 and Aβ oxidative stress treatments. In
addition, subcellular fractionation and subsequent immunoblotting of nuclear, cytosolic
and mitochondrial lysates could be performed to provide further support to localization
patterns of TERT in HT22 cell cultures transfected with the TERT plasmid. Furthermore,
time course experiments would provide insight to the maintenance of TERT in the
mitochondria in HT22 cells and may eliminate the variability of nuclear exclusion
observed in this study. Finally, analysis of the localization patterns of endogenous TERT
in a neuronal cell line would be ideal to rule out the possibility of mis-localization of
highly expressed ectopic TERT following transient transfection.
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4.3

TERT affects metabolism under oxidative stress

4.3.1

TERT shifts metabolism towards aerobic glycolysis

Enzymes involved in glycolysis were upregulated in TERT overexpressing cells exposed
to low or high concentrations of H2O2 and Aβ induced oxidative stress. There was an
increase in PDK1 protein levels and a concomitant increase in phospho-PDH/PDH ratio,
indicating that upregulation of PDK1 expression promoted PDH phosphorylation.
Phosphorylated PDH is inactive, thereby preventing the conversion of pyruvate to acetylCoA, which is needed for the TCA cycle and the generation of NADH to fuel the electron
transport chain in the inner mitochondrial membrane. There was also an increase in
LDHA protein levels, which catalyzes the conversion of pyruvate to L-lactate and limits
the use of pyruvate for mitochondrial metabolism. Finally, there was a decrease in the
PKM1/PKM2 ratio indicating higher PKM2 levels. Allosteric regulation allows PKM2 to
switch from a high-activity tetrameric state to a low-activity dimeric state139. The dimeric
form of PKM2 causes the accumulation of glycolytic intermediates and a shift towards
the PPP, an alternative pathway for glycolysis that generates NADPH, a reducing agent
used by antioxidant enzymes, ribose 5-phosphate needed for the synthesis of nucleotides,
and erythrose 4-phosphate needed for the synthesis of aromatic amino acids. Altogether,
these results demonstrate that TERT overexpressing cells combat H2O2 and Aβ induced
oxidative stress by limiting mitochondrial OXPHOS and shifting towards a glycolytic
phenotype. In addition, the increased growth of TERT-overexpressing cells under
control conditions may occur by TERT-mediated induction of aerobic glycolysis and
anabolic metabolism typical of cancer cells.
4.3.2

TERT may promote aerobic glycolysis by activation of HIF1-α

A proposed mechanism for TERT’s ability to shift metabolism during oxidative stress
may be through the activation of the alpha subunit of hypoxia induced factor 1 (HIF-1α).
Many types of cancers have an upregulation of HIF1-α activity which is a transcription
factor that increases expression of glucose transporters and enzymes within the glycolytic
pathway155. HIF1-α is known to induce the expression of LDHA, which is critical for
maintaining a reducing environment in order to combat ROS since it regenerates NAD+
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during the conversion of pyruvate to lactate, an essential co-factor for GAPDH, a key
glycolytic enzyme that converts glyceraldehyde-3-phosphate to 1,3bisphosphoglycerate156. HIF1-α also directly elevates PDK1 levels which limits the
conversion of pyruvate to acetyl-CoA to be used for OXPHOS, thereby shifting towards
glycolysis156. Furthermore, PKM2 has been reported to translocate to the nucleus to
promote the activation of HIF1-α and increased transcription of PKM2 in a feed forward
mechanism to alter metabolism157. Previously, HIF1-α has been linked to TERT as a
transcriptional regulator and can bind to the hTERT proximal promoter region through
two HIF-1α consensus binding sites to activate TERT transcription and enhance TERT
expression158–160. In addition, murine embryonic stem cells rely on HIF-1α to promote
TERT expression and maintain telomere length161.
However, the relationship between TERT and HIF-1α is yet to be explored in neurons
and other post-mitotic cells. In the current study, oxidative stress induced with H2O2 or
Aβ was unable to increase endogenous TERT expression in the HT22 cells, given that
there were no immunoreactive bands on Western blots probed with anti-TERT antibodies
in cell extracts from pcDNA transfectants. Therefore, it is possible that TERT acts as an
activator of HIF1-α instead. Mutations in the subunit ND2 of complex I has been shown
to increase ROS levels leads to a subsequent increase in HIF1-α levels in head and neck
squamous cell carcinoma162. Interestingly, TERT binds to mitochondrial DNA at the
coding region for ND2 and protects against oxidative stress-induced damage in human
umbilical vein endothelial cells, however the mechanism is unknown80. It is possible that
the binding of TERT to mitochondrial DNA at the coding region for ND2 may activate
HIF1-α to initiate metabolic changes that are protective against oxidative stress. Future
research should determine whether TERT can affect HIF-1α activity during oxidative
stress to elucidate potential feed-forward mechanisms for the metabolic changes caused
by TERT overexpression.
4.3.3

TERT may promote aerobic glycolysis by preventing activation of p66Shc

Another mechanism for the TERT-induced shift in metabolism may be via inhibition of
the 66-kilodalton isoform of the adaptor protein Src homology 2 domain containing
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protein (p66Shc), which plays major roles in redox balance, oxidative stress and
apoptosis163. Following phosphorylation on serine 36, p66Shc translocates to the
mitochondria where it increases mitochondrial ROS production and perturbs
mitochondrial membrane potential in favour of cytochrome C release164. Furthermore,
p66Shc has been linked to neurodegeneration via the opening of the permeability
transition pore (PTP) located on the OMM, which is a key event to initiate apoptosis165.
Phosphorylation of p66Shc can be achieved by kinases PKCβ and Jun NH2-terminal
kinase (JNK) which are activated by oxidative stressors such as H2O2 and Aβ
respectively166,167. In addition, p66Shc activation leads to a reduction in antioxidant
enzymes such as SOD, GPx and catalase, which further renders the cell susceptible to
toxic levels of ROS168. Interestingly, recent studies demonstrate that cells lacking p66Shc
shift their metabolism away from mitochondrial OXPHOS and towards aerobic
glycolysis, along with an increase in lactate production169,170. TERT may be able to shift
metabolism towards glycolytic pathways by preventing phosphorylation and subsequent
activation of p66Shc under oxidative stress conditions. Studies in our lab have shown that
Aβ can trigger phosphorylation and activation of p66Shc in HT22 cells (unpublished
observations). Moreover, inhibition of p66Shc expression leads to elevated aerobic
glycolysis and decreased sensitivity to Aβ toxicity. TERT has been shown to supress
caspase mediated apoptosis, and this is dependent on phosphorylation of JNK171. TERT
inhibition of JNK activation, and subsequent p66Shc phosphorylation, may promote a
shift towards aerobic glycolysis, decreased ROS production, and increased cell viability
under Aβ-induced oxidative stress. In addition, since localization of p66Shc and TERT
converge in the mitochondria, it is possible that TERT may directly interact with p66Shc
to prevent its phosphorylation and subsequent activation. Future studies should explore
whether TERT directly or indirectly influences p66Shc activation and explore possible
interactions between TERT and p66Shc within the mitochondria.
4.3.4

Metabolic alterations in TERT-deficient and TERT-overexpressing mice

Although the current study focuses on a cell culture model to examine the metabolic
effects of TERT under oxidative stress conditions, in vivo studies support the finding that
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TERT may alter metabolism and mitochondrial function. Metabolic changes in TERTdeficient and TERT-overexpressing mice are reviewed below.
First generation TERT knockout mice have no changes to fertility or identifiable
phenotypic change172. However, later generations have a significant reduction in telomere
length and lifespan compared to wild-type, leading to atrophy and functional decline of
proliferative (ex. intestine) as well as quiescent (ex. liver) organs, and infertility by the
fourth to sixth generation (G4-G6)173,174. Interestingly, G4 TERT-deficient mice have
severe metabolic and mitochondrial changes, especially in networks regulated by the
alpha and beta of peroxisome proliferator-activated receptor gamma coactivator-1 (PGC1α and PGC-1β), which control mitochondrial biogenesis and metabolic processes such
as OXPHOS, gluconeogenesis, fatty acid metabolism and β-oxidation175. When the liver
and heart mitochondria of G4 mice were examined, there was repression of OXPHOS
genes from all five ETC complexes, reduced activity of ETC complexes, reduced oxygen
consumption, decreased ATP synthesis, decreased levels of antioxidant enzymes
(catalase, GPx, SOD1) and increased mitochondrial ROS production174. In a separate
study, when G4 mice were fed a high fat, high sucrose diet for 8 weeks, there was
increased insulin resistance and glucose intolerance in liver and muscle tissue compared
to controls176.
TERT overexpressing mice exhibit improvement in metabolic decline during aging.
Constitutive expression of TERT in a mouse with a cancer resistant background was
shown to have delayed telomere shortening and an extension of median lifespan
accompanied by a youthful physiological profile, including delayed degenerative and
inflammatory age-related pathologies of organs such as the skin, intestine, kidney, liver
and brain177. In addition, these mice had improved glucose tolerance compared to aged
wild type controls177. When a metabolic profile of wild-type young and aged mice was
compared to the same TERT overexpressing cancer-resistant mice, aged TERT
overexpressing mice had a younger metabolic age compared with wild-type mice of the
same chronological age178. The same effect held true for aged mice receiving TERT gene
therapy via adeno associated virus vectors (AAV) in various stratified epithelia179. When
adult and old mice were given two months of TERT gene therapy, researchers observed
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improved insulin sensitivity and glucose tolerance, along with a reversal of the metabolic
signature associated with aging compared to age matched wild-type mice178,179.
Studies using TERT-deficient and TERT-overexpressing mice have provided evidence
supporting TERT’s ability to delay aging and to alter the metabolic profile of an
organism. However, research into the effect of TERT-deficiency or TERToverexpression on the metabolism of brain cells in vivo is lacking. In addition, it is
difficult to determine whether the protective effects observed in TERT-overexpressing
mice rely on restoring telomerase activity or if non-canonical functions of TERT are at
play. Based on the results of the present study, TERT-overexpression may be able to
improve age-related oxidative damage and neurodegeneration by altering metabolism in
favour of aerobic glycolysis, however this is yet to be confirmed in vivo.

4.4

TERT alleviates mitochondrial ROS production

The decrease in ROS production under H2O2 and Aβ oxidative stress treatments in TERT
overexpressing cells corroborates previous research, although a mechanism is still
speculative. As previously discussed, TERT can decrease ROS through improving
respiratory chain activity by decreasing succinate-linked respiration, complex I and IV
activity and UCP2 expression73,80,81. TERT has also been shown to increase the
availability of glutathione for GPx activity as well as promote more rapid recovery of
peroxidases from a hyperoxidized state81.
The change in PKM1/PKM2 protein levels in TERT overexpressing cells during H2O2
and Aβ treatments levels suggests a metabolic mechanism for alleviating ROS production
under oxidative stress treatment. As previously described, allosteric regulation allows
PKM2 to switch from a high-activity tetrameric state to a low-activity dimeric state139.
The dimeric form of PKM2 causes the accumulation of glycolytic intermediates and a
shift towards the PPP, which is an alternative pathway for glycolysis that promotes the
synthesis of nucleotides and aromatic amino acids180. The PPP also produces the reducing
factor NADPH that can be used for antioxidant enzymes and to recycle the anti-oxidant
glutathione needed for GPx activity, which may further contribute to the decreased ROS
effect observed in this study. Additional support arises from previous studies that
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demonstrate TERT overexpressing cells have higher reduced versus oxidized glutathione
compared to control cells81.
Future experiments should assess levels of NADPH in TERT overexpressing cells under
oxidative stress conditions to confirm if there is an upregulation of the PPP. In addition,
levels of reduced glutathione and GPx activity should be assessed to determine if changes
in antioxidant activity contributes to a reduction in ROS levels observed under Aβ
exposure in TERT overexpressing cells.

4.5

TERT improves cell viability

The MTT assay was used to reveal that TERT overexpressing cells have increased cell
viability and proliferative capacity under control and H2O2 or AB oxidative stress.
Immunofluorescence experiments illustrated that TERT localizes to the nucleus under
control conditions and has partial localization with the mitochondria under H2O2 and AB
oxidative stress treatments. This suggests that TERT may have nuclear as well as
mitochondrial functions that contribute to cell viability and proliferation.
4.5.1

TERT overexpression may reconstitute telomerase activity

Since TERC expression or telomerase activity was not tested in the current study, it is
possible that overexpression of TERT may reconstitute telomerase activity in
combination with endogenous TERC. This may lead to telomere elongation and a
subsequent increase in proliferative capacity of cells, as is expected with TERT’s
canonical function. Recently, an alternative TERC has been identified in the mouse brain
and has been shown to interact with both mouse and human versions of TERT, leading to
an increase in telomerase activity and increased cell survivability under H2O2 oxidative
stress181. Therefore, there is also the possibility of an alternative TERC present in the
mouse HT22 cell line that may reconstitute telomerase activity and contribute to
increased cell viability and proliferation in TERT overexpressing cells. Additional
experiments should be performed to ascertain TERC expression in HT22 cells and
whether overexpression of TERT restores telomerase activity and extends telomeres.
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4.5.2

TERT may have nuclear functions that contribute to cell viability

While it is possible that telomerase activity may contribute to improved cell viability,
previous research suggests that TERC expression is absent from hippocampal neurons
which express TERT46. Therefore, it is possible that TERT may influence cell viability in
HT22 cells in a TERC-independent manner. As previously discussed, TERT may act as a
transcription factor in the nucleus to increase the expression of genes involved in cell
growth and proliferation48. TERT interacts with p65 and p50 to influence transcription of
target genes of the redox sensitive transcription factor NF-κB55. Furthermore, estrogen
receptor activation was shown to increase TERT’s association with p65 and NF-κB and
protect against Aβ toxicity182. It is known that NF-κB can influence transcription of
antioxidants such as Mn SOD, metallothionein and glutathione-S-transferase183.
Therefore, TERT may be exerting its pro-survival effects through upregulating the
transcription of antioxidants targeted by NF-κB. Alternatively, TERT can increase
transcription of genes in the Wnt/β-catenin signalling pathway which is involved in stem
cell proliferation and self-renewal57. In addition to transcriptional regulation, TERT may
contribute to telomere capping and chromosomal structure, independent of telomere
lengthening58–61. To determine if TERT acts as a transcription factor to increase the
expression of pro-survival genes, future studies could use DNA microarrays or RNA-Seq
to identify genes that are upregulated or downregulated under H2O2 and Aβ induced
oxidative stress in TERT overexpressing cells.
4.5.3

TERT may have mitochondrial functions that contribute to cell viability

It is highly probable that TERT’s effect on cell viability arises from its mitochondrial
localization, since the mitochondria controls the cell’s intrinsic apoptosis pathway. As
previously discussed, TERT inhibition increases CC3 expression, decreases Bcl-2/Bax
ratio expression and reduces mitochondrial membrane potential in cultured neurons under
oxygen and glucose deprivation98. In addition, it was shown that TERT upregulated Bcl-2
and downregulated Bax and p53 in rat spinal cord motor neurons; events linked to TERTmediated anti-apoptotic effects99. Furthermore, it was established that TERT maintained
mitochondrial membrane potential in mouse hippocampal neurons exposed to Aβ133.
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Therefore, levels of Bcl-2/Bax, p53 and cleaved caspases as well as mitochondrial
membrane potential should be measured to determine if supressing the intrinsic apoptosis
pathway is a mechanism owing to the observed increase in cell viability in TERT
overexpressing cells under H2O2 and Aβ oxidative stress.

4.6

TERT is a potential therapeutic for Alzheimer’s Disease

4.6.1

Aβ25-35 treatment has the same effect as other Aβ species

It has been established that Aβ1-42 and Aβ1-40 are the predominant forms of Aβ within
insoluble extracellular plaques that interfere with cognitive function in AD184,185.
However, racemization of Aβ1-40 causes the in vivo conversion to the toxic Aβ25-35
fragment, which is also present in senile plaques and degenerated CA1 neurons in AD
brains186. It has been proposed that Aβ25-35 is the biologically active region responsible
for Aβ toxicity, since it is the shortest fragment able to form stable B-sheet aggregates
and induce neurotoxicity40–42. Similar to Aβ1-42, Aβ25-35 is able to spontaneously
transform from soluble oligomers to aggregated fibrils and the monomeric form of Aβ2535

is also cytotoxic190–192. A previous study has also characterized the effect of Aβ species

on rat brain mitochondria and reported similar effects with exposure to Aβ1-42 or Aβ25-35.
Both Aβ peptides accumulated in the mitochondria, caused declines in respiratory chain
complexes I, II and IV activity, and increased mitochondrial membrane viscosity, all
resulting in a strong inhibition of ATP synthesis193. In addition, there was an increase of
cytochrome C release upon Aβ1-42 or Aβ25-35 exposure193. Furthermore, additional studies
observed that Aβ1-40 or Aβ25-35 exposure results in pro-apoptotic effects such as increased
cleaved caspase 3 and 8, reduced Bcl-2/Bax protein ratio, loss of mitochondrial
membrane potential and mitochondrial DNA damage in murine cerebrovascular
endothelial cells132,194. Therefore, Aβ25-35 is an appropriate model to study the toxic
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effects of full length Aβ1-42 and it is expected that results generated with Aβ25-35 in this
study would yield parallel findings if other toxic species of Aβ were used. However, it
would still be worthwhile to compare the ability of exogenously expressed TERT to
protect against toxicity elicited by various species of Aβ1-42.
4.6.2

Metabolic alterations in AD may be mitigated with TERT

As previously described, patients with AD have reduced glucose uptake, altered glucose
metabolism and damage to mitochondrial components of OXPHOS110,111,113. These
metabolic characteristics are also reflected in transgenic mouse models of AD that
express the mutant forms of human genes encoding APP or PSEN1 to promote
amyloidogenic processing of the Aβ peptide. Researchers observe a downregulation of
mitochondrial biogenesis, decrease in activity and expression of OXPHOS complexes,
impaired glucose tolerance, and reduced insulin sensitivity in the hippocampus of 3 and 6
month old transgenic AD mice195. Thus, targets that combat the early metabolic changes
in hippocampal neurons caused by Aβ accumulation may prove to be effective in
delaying the progression of AD. The current study demonstrates that TERT is protective
against Aβ induced oxidative stress in a hippocampal neuronal cell line by altering
metabolism away from OXPHOS and towards aerobic glycolysis, leading to reduced
mitochondrial ROS production and improved cell viability. Given the results of this
study and previous studies that show mouse models using TERT gene therapy improves
glucose tolerance and insulin sensitivity, it stands to reason that TERT overexpression
may also be beneficial to mitochondrial function of hippocampal neurons exposed to Aβ
in vivo.
4.6.3

TERT can be used as a therapeutic agent without increasing cancer

TERT overexpression in somatic cells increases replicative lifespan of cells, but no
transformation to a malignant cancer phenotype occurs, even in the presence of
oncogenic HRAS expression196. Similar studies have confirmed that TERT
overexpressing somatic cells respond normally to contact inhibition, cell-cycle
checkpoints and growth arrest treatments and do not form tumors when injected into
mice, even when 10 times the amount of cells are used197–199. A possible explanation for
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this may be that most tumors with elevated hTERT expression occur after a mutation
arises in the tumor suppressor p53 gene, indicating that multiple mutations are needed for
a malignant phenotype37. These findings also extend to animal models. When adult and
old mice were given TERT gene therapy via adeno associated virus vectors (AAV),
researchers observed improved insulin sensitivity and glucose intolerance, decreased
incidence of osteoporosis, improved neuromuscular and object-recognition tasks and
extended lifespan, all without increasing tumorigenic activity179. Therefore, given the
evidence of TERT’s protective effects against Aβ toxicity presented in this study, ectopic
TERT expression could possibly be used as a therapeutic for AD and other
neurodegenerative diseases.

4.7

Final Remarks and Future Directions

The current study demonstrates that TERT partially localizes to the mitochondria under
H2O2 and Aβ induced oxidative stress and causes a shift in metabolism towards aerobic
glycolysis. In addition, mitochondrial ROS production was lessened during toxic Aβ
exposure and cell viability was improved with TERT overexpression. While these results
illustrate that TERT is protective against H2O2 and Aβ toxicity, further research is needed
to determine the mechanisms behind this effect.
Although one may argue that aerobic glycolysis is inefficient at producing ATP
compared to the mitochondria when measured per unit glucose, studies have proven that
the rate of ATP production through aerobic glycolysis is comparable to OXPHOS200,201.
While changes to metabolic enzymes in TERT overexpressing cells during oxidative
stress conditions provides compelling evidence in favour of aerobic glycolysis, future
experiments should measure glucose uptake, lactate production and oxygen consumption
to confirm. In addition, the rates of glycolysis versus OXPHOS should be measured using
other methods (Ex. Seahorse XF24 Analyzer) to confirm an increase in aerobic glycolysis
following oxidative stress treatment in TERT overexpressing cells.
It is not entirely clear whether nuclear or mitochondrial localization of TERT is providing
the observed benefits against oxidative stress. TERC expression and telomerase activity
should be assessed in TERT overexpressing cells to determine if TERT’s canonical
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function in the nucleus provides protection under H2O2 and Aβ induced oxidative stress.
In addition, modifications to TERT can be used to alter organelle localization. An
exclusively mitochondrial TERT could be engineered with a constitutive mitochondrial
targeting sequence at the amino terminus and deletion of the nuclear localization signal at
amino acid residues 222-240. Alternatively, nuclear export of TERT can be inhibited by
increasing activity of Shp2 or the 14-3-3 signalling protein along with deletion of the
nuclear export signal located at the C-terminus of TERT. Furthermore, the RT domain of
TERT should be removed or mutated to determine whether the protective effects are
dependent on the catalytic function of TERT. Then, protein levels of metabolic enzymes,
mitochondrial ROS production and cell viability can be assessed after exposure to toxic
levels of H2O2 and Aβ in HT22 cell cultures overexpressing either nuclear/mitochondrial- targeted and inactive/active TERT.
Due to the previous literature on TERT’s non-canonical mitochondrial functions, it would
be promising if the same metabolic shift, alterations in mitochondrial ROS production,
and changes in cell viability are observed with overexpression of a TERT protein
engineered to be constitutively mitochondrially located. The observation of TERT’s
ability to promote aerobic glycolysis under Aβ-induced oxidative stress suggests that
TERT gene or protein therapy may be a therapeutic for AD. However, further research is
needed to elucidate the mechanisms behind TERT’s metabolic and mitochondrial
functions in hippocampal neurons in vitro and in vivo.
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Appendix: Supplemental Figures and Tables
TERT Reverse primer- 5'{AGGTGAACCAGCACGTCG}3'
hCMV Promoter
CCCCCCNTATTGACGTCAATGNNCGGNNAAAATGGCCCGCCTNGNCNNTNATNNCCAGTACATGACCTNNTGNGACTT
TCCTACTNGNCAGTACANNNNACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTNGGCAGTACATCAATGGGCG
NNGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAAT
CAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTC

T7 Promoter
TATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGG

FLAG Epitope
AGACCCAAGCTTGGTACCAACATGGACTACAAGGACGACGATGACAAGGGAATTCCCGGGTCGACCCACGCGTCCGGG

hTERT sequence
CAGCGCTGCGTCCTGCTGCGCACGTGGGAAGCCCTGGCCCCGGCCACCCCCGCGATGCCGCGCGCTCCCCGCTGCCGA
GCCGTGCGCTCCCTGCTGCGCAGCCACTACCGCGAGGTGCTGCCGCTGGCCACGTTCGTGCGGCGCCTGGGGCCCCAGG
GCTGGCGGCTGGTGCAGCGCGGGGACCCGGCGGCTTTCCGCGCGCTGGTGGCCCAGTGCCTGGTGTGCGTGCCCTGGG
ACGCACGGCCGCCCCCCGCCGCCCCCTCCTTCCGCCAGGTGTCCTGCCTGAAGGAGCTGGTGGCCCGAGTGCTGCAGAG
GCTGTGCGAGCGCGGCGCGAAGAACGTGCTGGCCTTCGGCTTCGCGCTGCTGGACGGGGCCCGCGGGGGCCCCCCCGA
GGCCTTCACCACCAGCGTGCGCAGCTACCTGCCCAACACGGTGACCGACGCACTGCGGGGGAGCGGG

TERT Forward primer- 5'{CCCTCTGCTACTCCATCCTG}3'
hTERT sequence
CGCTGGGGGCCAGGGCGCCGCCGGCCCTCTGCCCTCCGAGGCCGTGCAGTGGCTGTGCCACCAAGCATTCCTGCTCAA
GCTGACTCGACACCGTGTCACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCCAGACGCAGCTGAGTCGGAAGCT
CCCGGGGACGACGCTGACTGCCCTGGAGGCCGCAGCCAACCCGGCACTGCCCTCAGACTTCAAGACCATCCTGGACGA

FLAG Epitope

SP6 Promoter

CTACAAGGACGACGATGACAAGTGATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGC

BGH Terminator
CTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTC
CCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGT
GGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTG

pMB1 ori
AGGCGGAAAGAACCAGTGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAA
AGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCA
TCACAAAAATCGACGCTCAAGTCAGANGTGGCGAANCCCGACAGGACTATNAAGATACCAGGCGTTTCCCCCTGGAAG
CTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACNGGATANCTGTNCGCCTTTCTCCCTTNNGGAAGCGNGGCGC
TTTCTCATAGCTCACGCTGNAGGTATCTCAGTTCGGTGTANGTCGTTCGCTCCAAG

Appendix 1: Sequencing Information of FLAG-TERT overexpression plasmid.
The 071 plasmid (referred to as FLAG-TERT) overexpression plasmid was provided
without a plasmid map so sequencing was performed by creating TERT Forward and
TERT Reverse primers to confirm coding of the FLAG epitope and the TERT protein.
The resulting sequencing information is provided in the 5’ to 3’ direction. Sequencing
revealed a FLAG epitope at the N- and C- terminus of TERT coding regions. Potential
start codons are highlighted in yellow.
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TERT Reverse primer- 5'{AGGTGAACCAGCACGTCG}3'
hTERT sequence
GANCATGGAGANCNNNNNNTTTGCGGGGNTTNNNNCGGGACGGGCTNNNTCNTGCNTTTTGNTGGATGANTTTCTNGT
TGGTGACACNNCACNTCACCCCACGCGAAAACCTTCCTCAGGACCNTGNTCCGAGNNTGTCCCTGAGTATGGCTGCGT
GGTGAACTTGCGGAAGACAGTGGTGAACTTNCCCTGTAGAAGACGAGGCCCTGGGTGGCACGGCTTTTGTTCAGATGC
CGGCCCACGGCCTATTCCCCTGGTGCGGCCTGNTGCTGGATACCCGGACCCTGGAGGTGCAGAGCGACTACTCCAGCTA
TGCCCGGACCTCCATCAGAGCCAGTCTCACCTTCAACCGCGGCTTCAAGGCTGGGAGGAACATGCGTCGCAAACTCTTT
GGGGTCTTGCGGCTGAAGTGTCACAGCCTGTTTCTGGATTTGCAGGTGAACAGCCTCCAGACGGTGTGCACCAACATCT
ACAAGATCCTCCTGCTGCAGGCGTACAGGTTTCACGCATGTGTGCTGCAGCTCCCATTTCATCAGCAAGTTTGGAAGAA
CCCCACATTTTTCCTGCGCGTCATCTCTGACACGGCCTCCCTCTGCTACTCCATCCTGAAAGCCAAGAACGCAGGGATG
TCGCTGGGGGCCAAGGGCGCCGCCGGCCCTCTGCCCTCCGAGGCCGTGCAGTGGCTGTGCCACCAAGCATTCCTGCTCA
AGCTGACTCGACACCGTGTCACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCCAGACGCAGCTGAGTCGGAAGC
TCCCGGGGACGACGCTGACTGCCCTGGAGGCCGCAGCCAACCCGGCACTGCCCTCAGACTTCAAGACCATCCTGGACG

FLAG Epitope
ACTACAAGGACGACGATGACAAGTGATCTAGAGGG

TERT Forward primer- 5'{CCCTCTGCTACTCCATCCTG}3'
hTERT sequence
CGCTGNNGGCNNAGGGCGCCGCCGGCCCTCTGCCCTCCGAGGCCGTGCAGTGGCTGTGCCACCAAGCATTCCTGCTCA
AGCTGACTCGACACCGTGTCACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCCAGACGCAGCTGAGTCGGAAGC
TCCCGGGGACGACGCTGACTGCCCTGGAGGCCGCAGCCAACCCGGCACTGCCCTCAGACTTCAAGACCATCCTGGACG

FLAG Epitope

SP6 Promoter

ACTACAAGGACGACGATGACAAGTGATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCA

BGH Terminator
GCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCAC
TCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGG
GTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTC

pMB1 ori
TGAGGCGGAAAGAACCAGTGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCA
AAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATANGCTCCGCCCCCCTGACGAG
CATCNCAAAANNCGACGCTCAAGTCAGANGTGGCGAANCCCGACAGGANTATAAAGATACCAGGCGTTTCCCCCTGGN
AANCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTA

Appendix 2: Sequencing Information of TERT overexpression plasmid.
The 072 (referred to as TERT) overexpression plasmid was provided without a plasmid
map so sequencing was performed by creating TERT Forward and TERT Reverse
primers to confirm coding of the TERT protein. The resulting sequencing information is
provided in the 5’ to 3’ direction. Although sequencing revealed a FLAG epitope at the
C-terminus of TERT, anti-FLAG antibodies could not detect FLAG by Western blot or
by immunofluorescence in 072 (TERT) transfected cells.
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Antibodies and Dyes
Target
hTERT
FLAG
TOM20
PDH
pSer232 PDH
PDK1
LDHA
PKM1
PKM2
HRP-conjugated
secondary mouse
HRP-conjugated
secondary rabbit
Alexa Fluor 488
Alexa Fluor 594
MitoTracker
CMXROS
MTT
DAPI (ProLong
Antifade Mountant
with DAPI)

Host
Rabbit polyclonal
Mouse monoclonal
Rabbit polyclonal
Mouse monoclonal
Rabbit polyclonal
Rabbit polyclonal
Rabbit polyclonal
Rabbit monoclonal
Rabbit polyclonal

Company
Rockland
Sigma
Santa Cruz
abcam
EMD Millipore
Enzo Life Sciences
Cell Signalling
Cell Signalling
Cell Signalling

Catalogue Number
600-401-252S
F3165
sc-11415
ab110334
AP1063
ADI-KAP-PK112-F
#2012
#7067
#3198

Goat

Santa Cruz

sc-2030

Goat

Santa Cruz

sc-2005

Sigma

R37120

Sigma

A-11008

---

Invitrogen

M7512

---

Sigma

M2003

---

Invitrogen

P36962

Goat anti-mouse
polyclonal
Goat anti-rabbit
polyclonal

Appendix 3: Table 1: List of antibodies and dyes.
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TOM20 + DAPI

FLAG

pcDNA
Control

30 µm

30 µm

30 µm

30 µm

30 µm

30 µm

pcDNA
400 µM
H2O2

pcDNA
25 µM
Aβ

Appendix 4: pcDNA transfected cells do not exhibit anti-FLAG immunoreactivity
following immunofluorescence staining.
Immunofluorescence staining of HT22 cells transfected with the pcDNA expression
construct. Cells were exposed to H2O2 (400 µM) or Aβ25-35 (25 µM) for 12 hours posttransfection and stained with anti-FLAG and anti-TOM20 antibodies. There is no visible
FLAG fluorescence in all treatments. (Green (FLAG), Red (TOM20), blue (DAPI). 40X
objective lens. Scale bars are 30 µm.
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Appendix 5: Dose Response Curve of HT22 cells following H2O2 exposure.
HT22 cells were seeded in 96 well plates at 7,000 cells/well then exposed to the indicated
concentrations of H2O2 for 24 hours. Cell viability was determined using the MTT assay
and expressed as a percentage of untreated cells. The LD50 was determined to be 0.67
mM.
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